S. Aliberti (Milan, Italy), H. Tiddens (Rotterdam, Netherlands)
Risk factors for lung disease progression in children with cystic fibrosis; a longitudinal cohort study K. van de Kant (Maastricht, Netherlands)
| |
Lumacaftor-Ivacaftor combination therapy in Phe508del homozygous CF patients with end-stage lung disease – preliminary results C. Murer (Luzern, Switzerland)
| |
Examining the effects of the Gly551Asp mutation on CT outcomes in children with cystic fibrosis L. Mok (Perth, WA, Australia)
| |
Nutritional status and pulmonary and respiratory muscle function in children and young people with cystic fibrosis N. Papalexopoulou (London, United Kingdom)
| |
Respiratory rate in infants with Cystic Fibrosis and healthy controls throughout the first year of life. I. Korten (Bern, Switzerland)
| |
Dynamic hyperinflation and daily physical activity in adults with cystic fibrosis D. Savi (Cantalupo in Sabina, Rieti, Italy)
| |
Observational study of respiratory tract microflora in CF patients over a 15-year period V. Sherman (Moscow, Russian Federation)
| |
Predicting the outcome of respiratory Pseudomonas aeruginosa infection in vivo A. Faniyi (BELFAST, United Kingdom)
| |
Does Pseudomonas status affect exercise capacity in CF? E. Hatziagorou (Thessaloniki, Greece)
| |
Functional magnetic resonance imaging and lung function tests in cystic fibrosis S. Nyilas (Bern, Switzerland)
| |
LCI in young children with CF – N2 or SF6? M. Stahl (Heidelberg, Germany)
| |
Potential utility of the N2 VC SBW test in cystic fibrosis (CF) S. Kjellberg (Skara, Sweden)
| |
Inter-test reproducibility of the lung clearance index measured by multiple breath washout E. Oude Engberink (Nijmegen, Netherlands)
| |
Real-time exhaled breath analysis identifies altered metabolic signature in cystic fibrosis T. Gaisl (Zürich, Switzerland)
| |